Galardi, Francesca
De Luca, Francesca
Biagioni, Chiara
Migliaccio, Ilenia
Curigliano, Giuseppe
Minisini, Alessandro M.
Bonechi, Martina
Moretti, Erica
Risi, Emanuela
McCartney, Amelia
Benelli, Matteo
Romagnoli, Dario
Cappadona, Silvia
Gabellini, Stefano
Guarducci, Cristina
Conti, Valerio
Biganzoli, Laura
Di Leo, Angelo
Malorni, Luca http://orcid.org/0000-0002-4297-2997
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (MFAG18880, MFAG14371)
Breast Cancer Research Foundation (19-037)
Article History
Received: 16 October 2020
Accepted: 8 March 2021
First Online: 24 March 2021
Declarations
:
: cTREnd was a pre-planned translational sub-study of TREnd (NCT02549430) and was run in parallel with TREnd under approval from the independent local ethics committees of each participating center. Separate informed written consent was prospectively obtained from patients joining in this sub-study.
: Not applicable
: LM is a consultant for Pfizer, Novartis, and Lilly and obtained research funding from Pfizer and Novartis. ADL Personal financial interests (honoraria, consulting or advisory role): Amgen, AstraZeneca, Athenex, Bayer, Celgene, Daiichi-Sankyo, Eisai, Genentech, Genomic Health, Ipsen, Lilly, Novartis, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Seattle Genetics, Sellas Life Sciences Group Institutional financial interests: Novartis. LB Personal financial interests (honoraria, consulting or advisory role): AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pfizer, Pierre Fabre, Roche, Takeda.Institutional financial interests: Celgene, Genomic Health, Novartis GC is a consultant for Pfizer, Novartis, Lilly, Astra Zeneca, Seattle Genetics, and Daichii Sankyo and obtained research funding from Merck and Roche. AM has an advisory role for Novartis, MSD, Pierre Fabre, Sunpharma. MB is a consultant for Novartis.